

BIO-INVESTIGATIONS LTD.

Stewart Rosenberg • President • 32 Country Way • Madison, CT 06443 U.S.A.
Phone/Fax **Direct: (203) 421-0028** Main: (203) 421-3697



<http://www.bioinvestigationstld.com>

Seeking Emerging Technologies Worldwide


5 February 2024

BIO-INVESTIGATIONS LTD. AND S&ST ANNOUNCE ADVANCEMENT OF SIFO GLOBAL COMMERCIALIZATION ACTIVITIES, WITH PROGRESS IN S&ST'S 2ND YEAR OF FINEP FINANCING

Madison, CT USA and Los Angeles, CA UNITED STATES OF
AMERICA

SIFO, or Side illuminated Fiber Optic Technology, is a transformational robust patent-backed Technology Platform that has commercial value for applications in the UV, visible and near infrared spectrums. SIFO has applications within multiple fields, including aerospace, industrial automotive markets, mobile devices, IT and datacom, broadband, medical devices, defense, fuel cell systems, oil and purification, indoor air quality, chemical manufacturing and agriculture.

The Brazilian arm of Science & Sensors Technologies, S&ST, Egalon Consultants, in conjunction with Microtube Ferramentaria de Precisão e Comércio LTDA (Microtube Precision Tooling and Trade LTD), announce a grant from the Brazilian funding agency FINEP, Financiadora de Estudos e Projetos (Financier of Studies and Projects). This grant seeks to implement SIFO technology in hydroponic platforms to measure liquid level, temperature, conductivity, and nutrient concentration in NFT (Nutrient Film Technique) systems. In the amount BRL 1.5M, approximately \$300K according to early January exchange rates, this grant is scheduled to continue from February 2022 through July 2025. To date, the



Copyright © 2020 by Claudio Oliveira Egalon

team led by S&ST has (1) successfully built and implemented a liquid level sensor based on SIFO and (2) effectively integrated commercially available conductivity and temperature probes into this sensor. S&ST is in the process of replacing these commercially available probes with SIFO-based concepts to further simplify its measurement device. It is also planning to automate its successful colorimeter platform and advanced prototype for individual nutrient measurements. Microtube is based in the city of Araraquara, state of São Paulo, Brazil. Claudio Egalon, PhD leads both S&ST in Los Angeles, USA and Egalon Consultants in São Paulo, Brazil. Dr. Egalon commented on the progress to date:



“It is remarkable the opportunities presented by this funding from FINEP, and the number of large corporations over which we prevailed. We appreciate this funding from FINEP to improve, automate and fine tune this application of our SIFO based products and technology platform.”

In addition, S&ST announces that it has also signed an 18-month ROFN, with Verivas Solutions Inc. (VSI), headquartered in Stamford, CT. This agreement will last until 28th of February 2025 and seeks to secure commercial partners within the medical space. Ross T. Lyon, MD, President and CEO of VSI, commented on the collaboration:

“SIFO is a transformational technology that has the potential to dramatically improve our sensing and imaging capabilities for diagnostic and therapeutic interventions in the medical field.”

Bio-Investigations Ltd. and S&ST have collaborated on the commercialization of SIFO since 2021.

For more information, please contact Stewart Rosenberg at (203) 376-7568.

Certain statements in this press release constitute forward-looking statements, are not historical facts, and involve risks and uncertainties that could cause actual results to differ from those expected and projected. Such risks and uncertainties may include, but are not limited to (i) general economic conditions; (ii) conditions specific to the industry; (iii) the company’s ability to develop or acquire new technology or products through licensing, merger or acquisition and to obtain regulatory approval to commercialize diagnostic, therapeutic or preventative products; (iv) the effectiveness and ultimate market acceptance of any such products; (v) limitations on third party reimbursements with respect to any such products; and (vi) competition. The company does not undertake to update or revise any forward-looking statements contained herein whether as a result of new information, future events or otherwise.

----- END -----